Efficacy and safety of apatinib treatment for gastric cancer, hepatocellular carcinoma and non-small cell lung cancer: a meta-analysis

Apatinib (Aitan(®), brand name in China) is a new anti-antiangiogenic agent that has recently been approved for the treatment of advanced gastric cancer (GC) in China. Nevertheless, its therapeutic efficacy against other types of advanced solid tumors remains unclear. This meta-analysis examines the...

Descripción completa

Detalles Bibliográficos
Autores principales: Xue, Jin-min, Astère, Manirakiza, Zhong, Mao-xi, Lin, Han, Shen, Jin, Zhu, Yu-xi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6160267/
https://www.ncbi.nlm.nih.gov/pubmed/30288047
http://dx.doi.org/10.2147/OTT.S172717

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6160267/
https://www.ncbi.nlm.nih.gov/pubmed/30288047
http://dx.doi.org/10.2147/OTT.S172717

Ejemplares similares